Trial Profile
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 27 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 10 May 2021 Planned End Date changed from 1 Apr 2022 to 1 Jun 2022.